EP4403632A3 — Antisense nucleic acids
Assigned to Nippon Shinyaku Co Ltd · Expires 2024-10-23 · 2y expired
What this patent protects
The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin g…
USPTO Abstract
The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Drugs covered by this patent
- Viltepso (VILTOLARSEN) · Nippon Shinyaku
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.